Compare LRE & RKTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LRE | RKTO |
|---|---|---|
| Founded | 2001 | N/A |
| Country | Japan | United States |
| Employees | N/A | 3 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.7M | 18.9M |
| IPO Year | 2022 | 2019 |
| Metric | LRE | RKTO |
|---|---|---|
| Price | $1.33 | $0.76 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 5.9K | ★ 5.2M |
| Earning Date | 07-30-2015 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.16 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.00 | $0.70 |
| 52 Week High | $2.86 | $1.19 |
| Indicator | LRE | RKTO |
|---|---|---|
| Relative Strength Index (RSI) | 42.20 | 42.06 |
| Support Level | $1.20 | $0.78 |
| Resistance Level | $1.38 | $0.84 |
| Average True Range (ATR) | 0.07 | 0.06 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 20.87 | 51.51 |
Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa Prefecture, and Sapporo. The company also operates hotels in Tokyo and leases apartment units to individual customers in Japan and Dallas, Texas. Its revenue is predominantly generated from developing and selling single-family homes and condominiums, hotel operations, and residential leasing. The company's sole operating segment is real estate sales. Geographically, it derives revenue from Japan.
Rocket One Inc is focused on developing and commercializing infrastructure for the orbital economy, including next-generation nanomagnetic AI chip technology designed for radiation-tolerant, energy-constrained environments such as low-Earth orbit, deep-space platforms, and defense systems. The company also intends to pursue opportunities related to nano-launch systems and nanosatellite deployment. In addition, its biotechnology operations, conducted through a wholly owned subsidiary, include development programs such as HT-001, HT-KIT, HT-ALZ, and a GDNF-based metabolic program.